Tapotoclax is under clinical development by Amgen and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase I drugs for Chronic Myelomonocytic Leukemia (CMML) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tapotoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMG-176 is under development for the treatment of higher-risk myelodysplastic syndrome, relapsed or refractory multiple myeloma, relapsed or refractory acute myeloid leukemia and chronic myelomonocytic leukemia (HR-MDS/CMML). It is administered through intravenous route. It acts by targeting Mcl-1. It was also under development for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Tapotoclax’s drug-specific PTSR and LoA scores, buy the report here.